Stockscreener 앱 받기
15.54
2.88%
-0.46
전일 마감가:
$16.00
열려 있는:
$16.03
하루 거래량:
898.86K
Relative Volume:
0.37
시가총액:
$2.56B
수익:
-
순이익/손실:
$-412.89M
주가수익비율:
-4.0259
EPS:
-3.86
순현금흐름:
$-361.93M
1주 성능:
-7.50%
1개월 성능:
-8.80%
6개월 성능:
+26.96%
1년 성능:
+10.60%
1일 변동 폭
$15.51
$16.53
1주일 범위
$15.51
$17.45
52주 변동 폭
$6.36
$25.00
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.54 | 2.63B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Whale Trades: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Earnings Report & Weekly Breakout Watchlists - baoquankhu1.vn
(DYN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Will Dyne Therapeutics Inc. benefit from current market trendsLong Setup & Daily Technical Forecast Reports - mfd.ru
Candriam S.C.A. Has $10.55 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling A 130% Potential Upside - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
History Review: Is now the right time to enter Dyne Therapeutics IncJuly 2025 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
Dyne Therapeutics Approaches Key Regulatory Milestones in 2026 - AD HOC NEWS
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Contender with a 108% Upside Potential - DirectorsTalk Interviews
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(DYN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pullback Watch: Can Dyne Therapeutics Inc scale operations efficientlyPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-01-28 16:56:14 - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling a 117% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - The Globe and Mail
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate - Sahm
FY2025 Earnings Forecast for DYN Issued By Lifesci Capital - MarketBeat
How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy? - Yahoo Finance
(DYN) Risk Channels and Responsive Allocation - Stock Traders Daily
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - 富途资讯
CEO Change: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Portfolio Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Powerhouse with 134% Upside Potential - DirectorsTalk Interviews
JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00 - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating - GuruFocus
Dyne Therapeutics (DYN) Gains Orphan Drug Status in Japan for DM - GuruFocus
Dyne Therapeutics Receives Orphan Drug Designation in Japan - GlobeNewswire
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Sahm
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. scale operations efficientlyMarket Rally & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Why Dyne Therapeutics Stock Was Crushing it This Week - AOL.com
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9%Here's What Happened - MarketBeat
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story? - simplywall.st
Analysts project 120% upside to Dyne Therapeutics, Inc. (DYN) - MSN
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Insider Monkey
DYN: Transformative clinical data and commercial launches planned for 2026–2027 in DMD and DM1 - TradingView
DYN: Transformative DMD and DM1 therapies advance toward 2027 launches, backed by validated platform - TradingView
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Why Dyne Therapeutics Inc stock appeals to analystsEarnings Risk Report & Risk Managed Investment Signals - Bộ Nội Vụ
Fed Meeting: Why Dyne Therapeutics Inc stock attracts high net worth investorsLong Setup & Long-Term Safe Investment Plans - Bộ Nội Vụ
Aug Gainers: Why Dyne Therapeutics Inc stock is trending among retail tradersTrade Ideas & Real-Time Sentiment Analysis - moha.gov.vn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Investing News Network
Downgrade Watch: Can Dyne Therapeutics Inc weather a recessionTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - Investing News Network
(DYN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):